Hanall Biopharma-NewDive, Agreement to Support Development of Developmental Disorder Treatment Platform

Park Seung-guk, CEO of Hanol Biopharma (left), and Cho Seong-ja, CEO of New Dive, are signing a support agreement and posing for a commemorative photo.

[Asia Economy Reporter Lee Gwanju] HanAll Biopharma announced on the 13th that it has signed a support agreement with NewDive, which is developing a metaverse-based remote social skills therapy program and customized artificial intelligence (AI) for children and adolescents with developmental disabilities.

Developmental disabilities refer to a state in which developmental milestones appropriate for age are not achieved, and are known to occur in 5-10% of all children. However, most treatment programs are not covered by insurance and require long treatment times, resulting in high time and financial burdens. Especially with the prolonged COVID-19 pandemic, face-to-face treatment has become difficult, sharply reducing treatment accessibility for adolescents with developmental disabilities.

NewDive was established in February to provide treatment programs tailored to the life cycle through digital healthcare solutions using 'real-world data' so that children and adolescents with developmental disabilities can live healthy lives, aiming to reduce patients' cost and time burdens.

NewDive’s platform is expected to improve social skills and problem-solving abilities of adolescents with developmental disabilities by creating situations very similar to reality through virtual reality (VR) and systematic multi-party interactions. Additionally, through AI algorithm development, it aims to provide customized treatment programs by learning and analyzing participants’ voice, response speed, facial expressions, and more.

Seungguk Park, CEO of HanAll Biopharma, said, “NewDive’s metaverse-based remote developmental rehabilitation treatment platform can provide treatment opportunities to many adolescents with developmental disabilities who were excluded from face-to-face treatment through innovation,” adding, “HanAll Biopharma will continue to support efforts to help patients suffering from diseases live better lives.”

Sungja Cho, CEO of NewDive, said, “Now adolescents with developmental disabilities can remotely experience various social situations without cost and time burdens and apply them in real life,” and added, “We are grateful to HanAll Biopharma for trusting NewDive’s technology and capabilities, and we will devote all efforts to developing digital therapeutics for adolescents with developmental disabilities.”

This content was produced with the assistance of AI translation services.